title: Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis.
abstract: In this review we discuss the current literature on the effects of type I interferons (IFN) and their downstream effectors on vascular growth in experimental models in vitro and in vivo. In addition to its well-documented role in angiogenesis, that is, the growth of new capillaries from existing vessels, we will also describe emerging evidence and mechanisms by which type I IFN may inhibit arteriogenesis, that is, the expansive remodeling of existing collateral arteries. Crucial in both processes is the common role of circulating monocytes, which are known to act as pivotal cellular modulators in revascularization through secreted chemokines, proteases, and growth factors. These secreted molecules, which are all modulated by IFN signaling, act via degradation of the extracellular matrix and by stimulating the proliferation of vascular smooth muscle cells and endothelial cells. Thus, next to the antiviral and immunomodulatory activities of type I IFNs, a potent role of IFN-β as modulator of revascularization is now emerging and may be considered a potential clinical target for the stimulation of angiogenesis and arteriogenesis in ill-perfused tissues.
authors.affiliation: 1 Department of Molecular Cell Biology and Immunology, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Cansu
authors.initials: C
authors.lastname: Yıldırım
authors.affiliation: 1 Department of Molecular Cell Biology and Immunology, VU University Medical Center , Amsterdam, The Netherlands .|2 Department of Cardiology, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Sylvia
authors.initials: S
authors.lastname: Nieuwenhuis
authors.affiliation: 2 Department of Cardiology, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Paul F
authors.initials: PF
authors.lastname: Teunissen
authors.affiliation: 1 Department of Molecular Cell Biology and Immunology, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Anton J G
authors.initials: AJ
authors.lastname: Horrevoets
authors.affiliation: 2 Department of Cardiology, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Niels
authors.initials: N
authors.lastname: van Royen
authors.affiliation: 1 Department of Molecular Cell Biology and Immunology, VU University Medical Center , Amsterdam, The Netherlands .
authors.forename: Tineke C T M
authors.initials: TC
authors.lastname: van der Pouw Kraan
mesh_terms: D000818:Animals; D001024:Aortic Valve Stenosis / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D001158:Arteries / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D005109:Extracellular Matrix / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D016899:Interferon-beta / Q000235:genetics / Q000276:immunology / Q000494:pharmacology*; D009000:Monocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D009024:Morphogenesis / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D017202:Myocardial Ischemia / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D032389:Myocytes, Smooth Muscle / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D018919:Neovascularization, Physiologic / Q000187:drug effects*
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D016899:Interferon-beta